Molecular adsorbent recirculating system treatment for acute liver failure

May 12, 2010

The molecular adsorbent recirculating system (MARS) is used in the treatment of liver failure patients to enable either native liver recovery or as a bridging treatment to liver transplantation. A recent study from Finland suggests that MARS treatment is both less costly and more effective than standard medical therapy in acute liver failure patients.

Numerous studies have documented the favorable effects of MARS albumin dialysis treatment on clinical and laboratory parameters and survival in liver failure patients. However, to ensure that limited resources are utilized in an ethical manner, the subjective feelings of the patient in terms of health-related quality of life and costs should also be taken into account. So far, only a few small non-randomized studies have focused on the cost-utility and the health-related quality of life of MARS-treated acute-on-chronic liver failure patients. Currently, there are no studies on the health-related quality or cost-utility of MARS treatment in (ALF).

The Helsinki MARS-study group, led by liver and transplant surgeon Helena Isoniemi, investigated the cost-utility and health-related quality of life in 90 MARS-treated ALF patients. Comparisons were made with a similar historical control group treated in the same . The 3-year outcomes and number of liver transplantations were recorded and all direct liver disease-related health care costs accrued during 3.5 years were determined. The health-related quality of life (HRQoL) before and after MARS was measured by using the 15D instrument. The HRQoL, cost, and survival data were combined and the incremental cost/quality-adjusted life year (QALY) ratio was calculated. This study is the first report evaluating the cost-utility of MARS treatment in ALF patients which will be published on May 14, 2010 in the .

Explore further: Dallas hospital confirms first Ebola case in US

More information: Kantola T, Mäklin S, Koivusalo AM, Räsänen P, Rissanen A, Roine R, Sintonen H, H√∂ckerstedt K, Isoniemi H. Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure. World J Gastroenterol 2010; 16(18): 2227-2234 www.wjgnet.com/1007-9327/full/v16/i18/2227.htm

add to favorites email to friend print save as pdf

Related Stories

Study shows lifetime effects of pediatric liver transplants

Mar 26, 2008

Parents of pediatric liver transplant recipients report lower health-related quality of life for their children two years after the surgery, compared to reports from the parents of healthy children. However, reports of family ...

Recommended for you

UN says Syria vaccine deaths was an NGO 'mistake'

3 hours ago

The recent deaths of Syrian children after receiving measles vaccinations was the result of a "mistake" by a non-governmental partner who mixed in a muscle relaxant meant for anesthesia, a spokesman for the U.N. secretary-general ...

First US child dies from enterovirus D68

3 hours ago

A child in the northeastern US state of Rhode Island has become the first to die from an ongoing outbreak of a respiratory virus, enterovirus D68, health officials said Wednesday.

US Ebola patient had contact with kids: governor

3 hours ago

A man who was diagnosed with Ebola in virus in Texas came in contact with young children, and experts are monitoring them for any signs of disease, governor Rick Perry said Wednesday.

UN worker dies of suspected Ebola in Liberia

4 hours ago

The United Nations mission in Liberia announced on Wednesday the first suspected victim among its employees of the deadly Ebola epidemic ravaging the impoverished west African nation.

User comments : 0